Tissue distribution of epirubicin after severe extravasation in humans.


Journal

Cancer chemotherapy and pharmacology
ISSN: 1432-0843
Titre abrégé: Cancer Chemother Pharmacol
Pays: Germany
ID NLM: 7806519

Informations de publication

Date de publication:
08 2021
Historique:
received: 04 01 2021
accepted: 14 04 2021
pubmed: 29 4 2021
medline: 18 9 2021
entrez: 28 4 2021
Statut: ppublish

Résumé

As critical parameter after extravasation of cytotoxic vesicants, anthracyclines were determined in removed tissue from patients requiring surgical intervention due to tissue necrosis. We monitored their distribution within the affected lesion to establish a possible dose-toxicity relation. From six patients scheduled for surgery, removed tissue flaps were systematically analysed by HPLC (epirubicin: 5 subjects; doxorubicin: 1 subject). After extravasation, tissue concentrations were highly variable with an individual anthracycline distribution pattern ranging from a few nanograms up to 17 µg per 100 mg tissue, which indicated a substantial difference in tissue sensitivity among patients. The resection borders coincided with the extension of the erythema and guided the surgical intervention after demarcation of the lesion, which occurred usually 2 or 3 weeks after extravasation. At that time, drug was hardly detected at the resection borders. Wound drains were negative for the extravasated drugs while showing a time profile of vascular growth factors and inflammatory cytokines, which was highly similar to routine surgery. In all six patients, surgical debridement with immediate wound closure led to healing within approximately 2 weeks, when therapy was resumed in all patients with reasonable time delay. Surgical intervention after demarcation of the extravasation lesion allows for almost uninterrupted continuation of treatment independent of the amount of extravasated anthracycline. As even minor amounts of the vesicants may trigger tissue necrosis, preventive measures merit the highest priority.

Identifiants

pubmed: 33907881
doi: 10.1007/s00280-021-04280-8
pii: 10.1007/s00280-021-04280-8
pmc: PMC8236455
doi:

Substances chimiques

Anthracyclines 0
Antibiotics, Antineoplastic 0
Antineoplastic Agents 0
Cytokines 0
Epirubicin 3Z8479ZZ5X
Doxorubicin 80168379AG

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

203-209

Références

J Cutan Pathol. 1989 Jun;16(3):158-63
pubmed: 2671070
J Educ Eval Health Prof. 2020;17:21
pubmed: 32668826
Ann Plast Surg. 1994 Jan;32(1):39-44
pubmed: 8141535
Support Care Cancer. 2015 Jun;23(6):1741-8
pubmed: 25433440
Cancer. 1989 Dec 15;64(12):2462-4
pubmed: 2819656
Ann Plast Surg. 2017 Nov;79(5):450-457
pubmed: 28906302
Ann Oncol. 2012 Oct;23 Suppl 7:vii167-73
pubmed: 22997449
Ann R Coll Surg Engl. 1988 Mar;70(2):105-8
pubmed: 3044237
PLoS One. 2014 Aug 21;9(8):e103649
pubmed: 25144707
PLoS One. 2011;6(5):e20492
pubmed: 21655269
Plast Reconstr Surg. 1978 Jan;61(1):86-92
pubmed: 339249
Surg Oncol Clin N Am. 1996 Oct;5(4):825-45
pubmed: 8899947
Metallomics. 2015 Mar;7(3):508-15
pubmed: 25659827
Rev Bras Enferm. 2020 Jun 17;73(4):e20190008
pubmed: 32578734
Eur J Surg Oncol. 2015 Mar;41(3):378-85
pubmed: 25515823
Plast Reconstr Surg. 1979 Apr;63(4):463-5
pubmed: 424456
J Hand Surg Am. 1983 Jan;8(1):32-8
pubmed: 6827049
Cancer. 1971 Oct;28(4):837-43
pubmed: 4329505
Ann Plast Surg. 2002 Oct;49(4):369-74
pubmed: 12370641
Cancer Chemother Pharmacol. 1980;5(1):17-20
pubmed: 7460191

Auteurs

Jakob Nedomansky (J)

Division of Plastic and Reconstructive Surgery, Department of Surgery, Comprehensive Cancer Center of the Medical University of Vienna, Vienna, Austria.

Werner Haslik (W)

Division of Plastic and Reconstructive Surgery, Department of Surgery, Comprehensive Cancer Center of the Medical University of Vienna, Vienna, Austria.

Ursula Pluschnig (U)

Department of Medicine I, Clinical Division of Oncology, Comprehensive Cancer Center of the Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.

Christoph Kornauth (C)

Department of Pathology, Comprehensive Cancer Center of the Medical University of Vienna, Vienna, Austria.

Christine Deutschmann (C)

Department of Obstetrics and Gynecology, Comprehensive Cancer Center of the Medical University of Vienna, Vienna, Austria.

Stefan Hacker (S)

Division of Plastic and Reconstructive Surgery, Department of Surgery, Comprehensive Cancer Center of the Medical University of Vienna, Vienna, Austria.

Günther G Steger (GG)

Department of Medicine I, Clinical Division of Oncology, Comprehensive Cancer Center of the Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.

Rupert Bartsch (R)

Department of Medicine I, Clinical Division of Oncology, Comprehensive Cancer Center of the Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.

Robert M Mader (RM)

Department of Medicine I, Clinical Division of Oncology, Comprehensive Cancer Center of the Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. robert.mader@meduniwien.ac.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH